Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets - PubMed (original) (raw)
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets
B C Tel et al. Neuroscience. 2002.
Abstract
Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the direct pathway.The equivalent marked losses of specific [3H]mazindol binding in the striatum of all drug treatment groups confirmed the identical nature of the nigral cell loss produced by MPTP treatment. MPTP-induced destruction of the nigro-striatal pathway markedly increased the level of PPE-A mRNA in the caudate nucleus and putamen and decreased the levels of PPT and PPE-B mRNA relative to normal animals. Repeated treatment with L-DOPA for 30 days produced marked dyskinesia but had no effect on the MPTP-induced increase in PPE-A mRNA in the caudate nucleus and putamen. In contrast, L-DOPA treatment normalised the MPTP-induced decrease in the level of PPT and PPE-B mRNA. Repeated treatment with ropinirole produced little or no dyskinesia but markedly reversed the MPTP-induced elevation in PPE-A mRNA in the caudate nucleus and putamen. However, it had no effect on the decrease in PPT or PPE-B mRNA. Similarly, bromocriptine treatment which induced only mild dyskinesia attenuated the MPTP-induced elevation in PPE-A mRNA in the caudate nucleus and putamen with no effect on reduced striatal PPT or PPE-B mRNA. Neither MPTP treatment nor treatment with L-DOPA, bromocriptine or ropinirole had any effect on adenosine A(2a) receptor mRNA in the striatum. These patterns of alteration in striatal PPE-A and PPT and PPE-B mRNA produced by L-DOPA, bromocriptine and ropinirole show differential involvement of markers of the direct and indirect striatal output pathways related to improvement of locomotor activity and mirror the relative abilities of the drugs to induce dyskinesia.
Similar articles
- Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T. Tamim MK, et al. Neuropharmacology. 2010 Jan;58(1):286-96. doi: 10.1016/j.neuropharm.2009.06.030. Epub 2009 Jul 2. Neuropharmacology. 2010. PMID: 19576910 - mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
Morin N, Morissette M, Grégoire L, Di Paolo T. Morin N, et al. Curr Neuropharmacol. 2016;14(5):481-93. doi: 10.2174/1570159x14666151201185652. Curr Neuropharmacol. 2016. PMID: 26639458 Free PMC article. Review. - Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments.
Jenner P. Jenner P. J Neurol. 2000 Apr;247 Suppl 2:II43-50. doi: 10.1007/pl00007760. J Neurol. 2000. PMID: 10991665 Review.
Cited by
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.
Hanrieder J, Ljungdahl A, Fälth M, Mammo SE, Bergquist J, Andersson M. Hanrieder J, et al. Mol Cell Proteomics. 2011 Oct;10(10):M111.009308. doi: 10.1074/mcp.M111.009308. Epub 2011 Jul 6. Mol Cell Proteomics. 2011. PMID: 21737418 Free PMC article. - The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.
de Lange EC. de Lange EC. Fluids Barriers CNS. 2013 Feb 22;10(1):12. doi: 10.1186/2045-8118-10-12. Fluids Barriers CNS. 2013. PMID: 23432852 Free PMC article. - Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Xiao D, et al. Brain Res. 2011 Jan 7;1367:310-8. doi: 10.1016/j.brainres.2010.08.099. Epub 2010 Sep 7. Brain Res. 2011. PMID: 20828543 Free PMC article. - µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Bezard E, Li Q, Hulme H, Fridjonsdottir E, Nilsson A, Pioli E, Andren PE, Crossman AR. Bezard E, et al. J Neurosci. 2020 Aug 26;40(35):6812-6819. doi: 10.1523/JNEUROSCI.0610-20.2020. Epub 2020 Jul 20. J Neurosci. 2020. PMID: 32690616 Free PMC article.